MYDECINE

News & Media

Mydecine Innovations kicks off machine learning-based drug discovery program with the University of Alberta

June 16, 2021
The program will enable the company to more rapidly screen hundreds of thousands of new molecules without the need to produce them.
Read More →

The Dales Report: Getting People to Help Changes Everything

June 11, 2021
William Cook, Interim CEO and Technical Director of the subsidiary company, MindLeap Health, talks about Version 2.0 of the MindLeap app launching soon.
Read More →

Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

June 8, 2021
A large majority appear to have never been reported before and could be vital to the critical effects of naturally-sourced mushrooms on human health and wellbeing.
Read More →

Mydecine to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference

June 3, 2021
Mr. Bartch’s corporate presentation will be available on-demand starting at 7:00 a.m. ET on June 17.
Read More →

The Dales Report: Microdosing, PTSD and Research: Mydecine COO Damon Michaels Talks Psychedelics

June 3, 2021
Part II: Michaels talks about the addressable market for PTSD, how quickly the industry for psychedelics is moving, and how big pharma may get involved.
Read More →

Mydecine COO Damon Michaels on Canada Cultivation and Mushroom Editing

May 31, 2021
COO discusses the expansion of its cultivation facilities in Canada, the possibility of genetically editing mushrooms, and the roadmap for next 12 months.
Read More →

Mydecine wins Health Canada approval for expanding cultivation capabilities for psilocybin producing mushrooms

May 25, 2021
Chief Science Officer Rob Roscow said it will “enhance” the firm’s ability to “produce pharmaceutical-grade psilocybin at scale”
Read More →

Psychedelic Solutions: How Mydecine Innovations Group is Working to Solve the Mental Health Crisis

May 25, 2021
Mydecine Innovations Group is a key force driving this innovation and is bridging the gap between the two industries.
Read More →

Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

May 19, 2021
Company intends to spin off its U.S. cannabis assets and its interests in U.S. cannabis projects into a newly incorporated subsidiary (“SpinCo”).
Read More →

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

May 18, 2021
Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics.
Read More →

Mydecine to Participate in the Benzinga Global Small Cap Conference on May 13th

May 10, 2021
Mydecine CEO Josh Bartch will speak on the panel titled Investing in the Mental Health Crisis Through Psychedelics.
Read More →

Mydecine CSO Rob Roscow Joins The Dales Report Podcast

May 6, 2021
Roscow talks Mydecine’s upcoming phase 2a clinical trials on psylocibin-assisted PTSD treatments, barriers presented by COVID, and the new novel drug candidates.
Read More →

Mydecine Announces Partnership with LeadGen Labs

May 5, 2021
LeadGen Labs partnership will considerably increase Mydecine’s synthesis capabilities of novel molecules.
Read More →

Mydecine Reports Full Year 2020 Financial Results and Provides Business Update

May 3, 2021
Strengthened Balance Sheet with Approximately $30 Million in Capital Raised Subsequent to the Year-End.
Read More →

Mydecine Innovations Group Inc. (MYCOF) CEO Josh Bartch on Q4 2020 Results - Earnings Call Transcript

May 3, 2021
Participants include Josh Bartch - Co-founder, Chairman and CEO; Dean Ditto - Chief Financial Officer; and Allison Soss - Investor Relations.
Read More →

Mydecine Innovations Group’s Joshua Bartch joins the Psychedelic Spotlight podcast

April 28, 2021
Podcast discusses the company's novel research protocols, its relationship with legal psilocybin growers in Jamaica, and the future for psychedelic therapy.‍
Read More →

Mydecine to Report Full Year 2020 Financial Results on May 3, 2021

April 26, 2021
Company will host a conference call and audio webcast that morning at 10:30 a.m. ET featuring remarks by Josh Bartch, CEO and Dean Ditto, CFO.
Read More →

Biotech Companies Driving Psychedelics Industry Forward with Key Research

April 13, 2021
Mydecine and other companies are looking into natural medicine initiatives to improve the quality of life of individuals struggling with mental health disorders.
Read More →

Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening

April 13, 2021
Move represents next steps in company's research and development process as it investigates the chemical compounds and potential therapeutic effects of natural psilocybin.
Read More →

Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical

April 7, 2021
Mydecine believes that these drug candidates are unique and patentable in the United States and Canada.
Read More →

Psychedelic Experience ‘Promising’ in Treating PTSD – Mydecine CMO Dr. Rakesh Jetly

March 30, 2021
Podcast discusses how the psychedelic experience is key to treating PTSD and how it may teach us about how psychedelics make the brain open to new ideas.
Read More →

Mydecine Innovations Group Graduates Listing To NEO Exchange

March 23, 2021
Fast growing biotech company becomes latest in a wave of migrations and graduations to the NEO Exchange.
Read More →

CSO Rob Roscow: Transforming Research From Mydecine’s 3 Pillars Into Repeatable Medicine

March 23, 2021
Shadd Dales talks with Mydecine Innovations Chief Science Officer Rob Roscow about Mydecine’s three main operational pillars: IP/R&D, Clinical Trials and Technology.
Read More →

What are your favorite publicly traded companies in the psychedelic sector?

March 19, 2021
Vote for the public companies that are leading the emergence of psychedelics as a form of mental health treatment.
Read More →

Mydecine CEO Josh Bartch on the Future of Psychedelics

March 18, 2021
With recent landmark progress in legalization efforts around the world, it’s clear we are in a psychedelic renaissance.
Read More →

The Window of Opportunity is Here

March 18, 2021
­In depth look at how psychedelic mental health solutions are gaining steam with elite athletes and researchers.
Read More →

Mydecine Innovations Group Provides Update on European Operations

March 16, 2021
Mydecine appoints former Novartis Norway CEO Michel Rudolphie as President of European Operations and partners with Dr. David Erritzoe for research.
Read More →

Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Asset

March 10, 2021
Mydecine’s principal business will focus on the development and commercialization of solutions for treating mental health problems through its psilocybin research and development.
Read More →

Mydecine Co-Founder Damon Michaels: It’s Time To Make Alternative Medicine Modern Medicine

March 9, 2021
The chief operating officer sat down with The Dales Report last week to discuss the company’s latest activity.
Read More →

Mydecine Innovations’ Josh Bartch: The Last 12 Months Have Been Monumental For The Industry

March 4, 2021
Josh Bartch, Co-Founder & CEO of Mydecine, talks to Shadd Dales of The Dales Report to put recent company events in context.
Read More →

Mydecine Innovations Group cultivating low-cost psilocybin mushrooms at scale to treat PTSD

March 4, 2021
CEO Joshua Bartch tells Proactive the Colorado-based emerging biotech and life sciences company is making tremendous advancements.
Read More →

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

March 1, 2021
Milestone means Mydecine is now able to access a quality source of product for research purposes and to sell and transfer to other licensed global research facilities.
Read More →

Mydecine Innovations: Unlocking Fungi’s Pharmacological and Nutraceutical Healing Properties

March 1, 2021
The Dales Report takes a look at Mydecine Innovations Group and its position in the world of early-stage psychedelic investing.
Read More →

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

February 24, 2021
Partnership Supports Mydecine’s Drug Development and Clinical Trials Pipeline; Provides Update on Debt Settlement.
Read More →

Behind the World-First Export of Jamaican Psilocybin Mushrooms

February 19, 2021
Mydecine’s Chief Scientific Officer and Co-Founder Rob Roscow talks first harvest and commercial export of legal psychedelic psilocybin mushrooms.
Read More →

Truffle Talk with Joshua Bartch of Mydecine Innovations Group

February 18, 2021
Co-founder and CEO Joshua Bartch speaks to Truffle Report about the company’s psychedelics research program.
Read More →

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technolog

February 17, 2021
Digital health platform will combine telemedicine, on-demand mental health programs and advanced wellbeing analytics.
Read More →

Mydecine Innovations Group Partners with Microdose to Present a Webinar on Psychedelic Drug Development

February 16, 2021
Mydecine panelists will discuss if Psychedelic Drug Design can Improve Safety and Efficacy for Medicine.
Read More →

Magic mushroom therapy could help treat PTSD in Canadian military vets

February 16, 2021
Mydecine's Chief Medical Officer offers a few hypotheses as to why PTSD in veterans can be difficult to treat.
Read More →

Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

February 12, 2021
Offering further strengthens Mydecine’s balance sheet and positions the Company for continued growth in 2021.
Read More →

The Current Status of Psychedelics in Psychiatry

February 4, 2021
Mydecine Innovations Group Advisory Board Member Robin Carhart-Harris, PhD and David Nutt, MD, PhD provide viewpoint on industry progress.
Read More →

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

February 3, 2021
Wu brings in an extensive network of experts in operation, clinical, market positioning and regulatory knowledge in the Pan Asia healthcare landscape.
Read More →

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

February 1, 2021
With the move, the company is positioning its common shares to be traded on a senior exchange in Canada, providing exposure to more investors.
Read More →

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

January 28, 2021
The research goal is to get a better understanding of when, where and how psilocybin is most appropriate for use in human therapeutics.
Read More →

Mydecine Innovations Group Files Application to list to the NASDAQ

January 27, 2021
Mydecine submitted a formal application to list its common shares on the second largest exchange by market capitalization worldwide.
Read More →

Research and Development Moves the Psychedelics Market Forward

January 27, 2021
FN Media Group presents Microsmallcap.com market commentary on the companies that are commercializing psychedelic medicines.
Read More →

Microdosing Mysteries: The New Science Exploring Tiny Doses of Psychedelics

January 24, 2021
New Atlas's Flipboard aggregates some of the top stories from around the world on the subject of psychedelics.
Read More →

Mydecine Innovations Group Included in First-Ever Psychedelics ETF

January 22, 2021
Mydecine is one of 17 companies to be included in the Horizons Psychedelic Stock Index Exchanged Traded Fund (ETF).
Read More →

Mydecine Innovations Group Files Preliminary Prospectus

January 21, 2021
Prospectus filing is in connection with its bought deal offering previously announced on January 14, 2021.
Read More →

Mydecine Co-founder and CEO sees a big future for psilocybin and other mushroom-based compounds

January 17, 2021
Josh Bartch highlights how Mydecine Innovations Group is well positioned in the pharmaceuticals and consumer packaged goods industries.
Read More →

Researchers will soon test psychosubstances as a potential treatment for veterans with PTSD.

January 14, 2021
Mydecine's Rakesh Jetly, MD joins HCPLive® to talk about how research is on the cutting edge of a breakthrough treating trauma.
Read More →

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

January 14, 2021
The emerging biopharma and life sciences company announces that it has entered into an agreement with Canaccord Genuity Corp.
Read More →

Mydecine Innovations Group Upsizes Previously Announced Bought Deal

January 14, 2021
Mydecine announces that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp.
Read More →

Mydecine Innovations Group Uniquely Positioned To Take Over 2021

January 13, 2021
Microdose Psychedelic Insights, which provides Psychedelic industry insight and market intelligence, believes the future is bright for Mydecine.
Read More →

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

January 11, 2021
MYCO Continues to Strengthen Board of Directors in Anticipation of Senior Exchange Listing Requirements.
Read More →

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

January 11, 2021
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Read More →

5 Groovy Psychedelic Stocks to Buy

January 8, 2021
Investor Place reports that “The Times They Are A-Changin’” for psychedelic mental health treatments.
Read More →

Mydecine Innovations Group Shares Intellectual Property Update

January 7, 2021
Mydecine Innovations Group files seven provisional patent applications with United States Patent and Trademark Office.
Read More →

Further Research into Psilocybin Opens New Doors for Treatment

January 7, 2021
Financial Buzz highlights five companies, including Mydecine Innovations Group, that are leading research efforts into Psilocybin.
Read More →

2020 Was A Year of Historic Firsts That Set the Stage for the Psychedelic Renaissance

January 6, 2021
Microdose Psychedelic Insights breaks down all the psychedelic industry advancements made in the year 2020.
Read More →

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

January 5, 2021
Study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.
Read More →

The Year In Review For Psychedelic Drug Stocks: 2020

December 23, 2020
Multi-bagger returns for several companies; Large and rising capital flows into the industry; Very favorable media coverage and public opinion.
Read More →

Psychedelic Scientist Robin Carhart Harris Leads The Research Renaissance With Over 100 Peer-Reviewed Publications

December 23, 2020
Highlighting notable scientific achievements Harris has made towards advancing the psychedelic renaissance.
Read More →

Psychedelics Industry Gearing Up For an Even Bigger 2021

December 21, 2020
Mydecine Innovations Group is focused on developing and commercializing innovative solutions to treat mental health problems and enhance well being.
Read More →

Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials

December 21, 2020
Mydecine has engaged ethica CRO, a full-service Contract Research Organization (“CRO”) that conducts and manages ethical clinical research.
Read More →

Mydecine Speaker Series: Psychedelic Solutions

December 21, 2020
Mydecine panellists discuss psychedelic solutions in speaker series moderated by Business Insider journalist Yeji Lee.
Read More →

2020: A Year In Review for the Psychedelic Renaissance

December 20, 2020
The year 2020 has been a really big year for magic mushrooms and the fast-paced growth of psychedelic medicine.
Read More →

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

December 15, 2020
Leading FDA consultancy firm ProPharma Group to advise on drug development and clinical trial pipeline.
Read More →

Push for Alternative Therapies Prods Researchers Towards Psilocybin

December 15, 2020
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends, provides update on Mydecine.
Read More →

Mydecine to make first legal import of psilocybin mushrooms into Canada

December 11, 2020
Canada continues to open the door for clinical research the effectiveness of psilocybin for mental health treatments.
Read More →

Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics

December 10, 2020
Panelists will discuss the impact of cutting edge research in mainstream medical interest about unlocking the potential of psychedelic therapies.
Read More →

Top Mushroom Penny Stocks To Watch For 2021

December 10, 2020
Are you Looking For Top Mushroom Stocks Right Now? Psychedelic Stocks To Watch Heading Into The New Year.
Read More →

Psychedelics: FDI’s next trip?

December 9, 2020
Psilocybin-based therapies are gaining ground in the US, sparking investment in the sector with a recent rush of investor interest.
Read More →

Psychedelic Quick Hits: Havn Life, MindMed, Mydecine

December 9, 2020
The cannabis industry's leading financial news source highlights Mydecine's first commercial harvest of natural psilocybin mushrooms.
Read More →

Spotlight: Dr. Denton Hoyer, Scientific Advisor, Mydecine

December 9, 2020
Hoyer shares his insight into psychedelic derived medicines, his experience with large Pharma companies, and what he's working on at Mydecine.
Read More →

Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

December 8, 2020
Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybin.
Read More →

Health Crisis-Induced Post-Traumatic Stress Disorder Creates Growing Need for Treatment Options

December 8, 2020
FN (Financial News) Media Group Presents Microsmallcap.com Market Commentary with Updates on Mydecine Innovations Group.
Read More →

Plant Medicine Expands into New Realms

December 8, 2020
Webcast: From Cannabis to Mycology, Damon Michaels of Mydecine talks about his transition with Genifer Murray on Inside the Industry.
Read More →

Understanding The Psilocybin Supply Chain: Every Production Method Explained

December 2, 2020
As psychedelics-assisted therapy gains momentum, investors need to understand the difference between the current available means of obtaining psilocybin.
Read More →

Q&A Spotlight: Dr. Rakesh Jetly, Chief Medical Officer, Mydecine

November 30, 2020
Jetly discusses his background and viewpoints on a variety of topics in the world of psychedelics and the treatment of PTSD in soldiers.
Read More →

Clinical trial explores psychedelic treatments for PTSD in veterans

November 25, 2020
A company exploring the efficacy of psychedelic treatments for PTSD in veterans has announced the international expansion of its Phase 2A clinical trials.
Read More →

Psychedelics Transition from Experimental Treatment to Major Pharmaceutical Industry

November 20, 2020
Mydecine Innovations Group Inc. is an emerging biopharma and life sciences company that is committed to the research, development and acceptance of alternative nature-sourced medicine.
Read More →

Is Compass Pathways Stock a Buy?

November 18, 2020
Oregon just decriminalized the use of the psychedelic compound psilocybin. Could Compass Pathways, which is testing a synthetic form of the drug as a mental health therapy, be on the cusp of something big?
Read More →

Mydecine Innovations Group Offers Management and Clinical Trials Update

November 17, 2020
Company Announces International Expansion of Clinical Trial Sites for Phase 2A Study into Psychedelic Treatments for PTSD in Veterans.
Read More →

More U.S. Military Funding For Psychedelic Drug R&D As PTSD Crisis Worsens

November 16, 2020
From crisis comes opportunity. The worsening PTSD crisis among military personnel (and first responders) may be the quickest path to legalization for a new psychedelic medicine.
Read More →

MYCO Times: Newsletter (November)

November 9, 2020
Get the latest news from Mydecine Innovations Group, Inc. including a note from Chairman and CEO Joshua Bartch.
Read More →

Magic Mushroom Compound Called Psilocybin May Help Treat Depression

November 7, 2020
New study says psychedelic substance found in magic mushrooms can relieve symptoms in people with major depressive disorder.
Read More →

Mydecine Innovations Group Retains KCSA Strategic Communications

November 6, 2020
The fully integrated communications agency to provide public relations and social media counsel for the emerging biopharma and life sciences company.
Read More →

Q&A Spotlight: Robert Roscow, CSO at Mydecine Innovations Group

November 3, 2020
Roscow has set his focus on the vast healing potential of the safe and effective compounds found in fungi.
Read More →

Exploring Non-Dilutive Grant Funding for Clinical Trial Initiatives: Q&A with Mydecine CEO Josh Bartch

October 22, 2020
Mydecine's CEO Josh Bartch talks therapeutic medicine funding and market listings with the editor-in-chief of IPO-Edge.
Read More →

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

October 16, 2020
A listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.
Read More →

NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

October 14, 2020
A wide range of government and private non-dilutive funding sources are available for the disorders being addressed by NeuroPharm.
Read More →

Numinus (CSE:NUMI) or Mydecine (CSE:MYCO)? Two Psychedelics Investing Options

October 14, 2020
‍The two industry leaders among psychedelic stocks have already carved out their own followings among psychedelic stock investors.
Read More →

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores

September 30, 2020
Mindleap's digital telehealth mobile application for mental coaching and wellbeing is now available for download.
Read More →

Mindleap Launches Digital Platform Intended For Psychedelic Aftercare

September 24, 2020
Green Market Report reports Mindleap Health has launched a digital health platform that combines telehealth with mood, emotion, and habit tracking.
Read More →

New App, Mindleap, Aims To Revolutionize Psychedelic Use And Wellness

September 24, 2020
High Times article details a new Mindleap app that connects mental health professionals with people using psychedelics.
Read More →

Psychedelics Companies Look To 'Functional Mushrooms' For Opportunities

September 21, 2020
In recent years mushrooms left their dark, hidden habitats to jump into the spotlight of consumer markets.
Read More →

Mydecine Innovations Group Would Like to Give Thanks to its Shareholders for Extending the Lockup on the Five Cent Placement for Another 120 Days

September 3, 2020
MIG shareholders have agreed to extend lock-up restrictions that were due to be released on September 6, 2020, for an additional 120 days.
Read More →

Mydecine Innovations Group Completes Acquisition of NeuroPharm Inc.

September 3, 2020
Mydecine Innovations Group Inc. has closed its previously announced acquisition of NeuroPharm Inc., a developer of natural health, psychedelic-based treatments for post-traumatic stress disorder and other serious mental health disorders.
Read More →

The Trip Report: Psilocybin Cultivation and Delivery Trends

August 24, 2020
Industry newsletter The Trip Report highlighted Mydecine as one of the few companies planning to produce psilocybin from natural products.
Read More →
← Back to homepage